Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of erythritol in preparation of medicine for treating non-alcoholic fatty liver

An erythritol, non-alcoholic technology, applied in the field of application of erythritol in the preparation of drugs for the treatment of non-alcoholic fatty liver, can solve the problems of no research and reports on the therapeutic effect

Inactive Publication Date: 2021-04-20
JILIN UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are no studies and reports on the therapeutic effect of erythritol on non-alcoholic fatty liver disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of erythritol in preparation of medicine for treating non-alcoholic fatty liver
  • Application of erythritol in preparation of medicine for treating non-alcoholic fatty liver
  • Application of erythritol in preparation of medicine for treating non-alcoholic fatty liver

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 AML12 Cell Oil Red O Staining Experiment

[0033] experimental method:

[0034] (1) AML12 cells were cultured and seeded in six-well plates. The formula of cell culture medium is F12 medium with 4.5g / L glucose, 10% fetal calf serum, 1% penicillin and streptomycin, 1% ITS, 40ng / ml dexamethasone (Sigma, D4902-100mg). Cells were cultured in 5% CO 2 and in a cell culture incubator at 37°C for 12 hours.

[0035] (2) Remove the original culture medium and replace it with F12 with only 4.5g / L glucose as the culture medium to culture the cells, and starve the AML12 cells for 3 hours.

[0036] (3) AML12 cells were co-incubated with 250 mg / ml erythritol and 1000 μM free fatty acid (oleic acid:palmitic acid=2:1) ​​for 24 hours; among them, they were divided into blank group (F12 medium), model group (1000 μM free fatty acid ), control group (250mg / ml erythritol), experimental group (250mg / ml erythritol+1000μM free fatty acid).

[0037] (4) The cell culture medium wa...

experiment example 2W

[0044] Experimental example 2Western blot detection of lipid regulatory protein expression in HEPG2 cells

[0045] experimental method

[0046] (1) Culture HEPG2 cells and inoculate them in a six-well plate with a density of 1×10 per well 6 cells. The formula of the cell culture medium is DMEM medium with 4.5g / L glucose, 10% fetal bovine serum and 1% penicillin and streptomycin. Cells were cultured in 5% CO 2 and in a cell culture incubator at 37°C for 12 hours.

[0047] (2) Remove the original culture medium and replace it with DMEM with only 4.5g / L glucose as the culture medium to culture the cells, and starve the HEPG2 cells for 3 hours.

[0048] (3) Co-incubate HEPG2 cells with 250 mg / ml erythritol and 1000 μM free fatty acid (oleic acid:palmitic acid=2:1) ​​for 24 hours; wherein, they are divided into blank group (DMEM medium), model group (1000 μM free fatty acid ), control group (250mg / ml erythritol), experimental group (250mg / ml erythritol+1000μM free fatty acid)....

Embodiment 3

[0058] Determination of TG in the mouse liver of embodiment 3

[0059] experimental method:

[0060] (1) Raise the mice in an SPF environment with a temperature of 24±1° C. and a relative humidity of 40%-80%.

[0061] (2) Before the experiment, the mice were separated into cages and fasted for 12 hours, and then injected intraperitoneally with 50 mg / kg, 100 mg / kg, and 200 mg / kg of erythritol for 1 hour and then injected with 500 mg / kg of tyloxapol Mice were injected intraperitoneally for 12 hours. The mice were randomly divided into seven groups: blank group (normal saline), model group (500mg / kg tyloxapol), control group (200mg / kg erythritol), drug low dose group (50mg / kg erythritol sugar alcohol+500mg / kg tyloxapol), drug middle dose group (100mg / kg erythritol+500mg / kg tyloxapol), drug high dose group (200mg / kg erythritol+500mg / kg Tyloxapol), drug positive control group (100mg / kg fenofibrate+500mg / kg Tyloxapol).

[0062] (3) The mouse liver was completely removed and cut ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of erythritol in preparation of a medicine for treating non-alcoholic fatty liver. Pharmacological experiments show that the erythritol has a good treatment effect on a non-alcoholic fatty liver mouse model and a hepatocyte lipid accumulation model. Experimental results prove that the erythritol can effectively reduce the lipid content in hepatocytes by regulating expression of acetyl-coenzyme A carboxylase (ACC) and cholesterol regulatory element binding protein 1c (SREBP-1c) in hepatocytes; In mice with non-alcoholic fatty liver, the erythritol can significantly reduce lipid accumulation in the liver and can significantly inhibit the levels of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase. In a word, the erythritol can play a role in regulating the blood fat by inhibiting the expression of SREBP-1 and ACC.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of erythritol in the preparation of medicines for treating non-alcoholic fatty liver. Background technique [0002] Non-alcoholic fatty liver (NAFLD) is a series of syndromes caused by liver parenchymal cell degeneration and fat accumulation caused by non-alcoholic effects. According to whether the lesion tissue is accompanied by inflammation and fibrosis, it can be divided into simple fatty liver , steatohepatitis and its associated cirrhosis and hepatocellular carcinoma. Non-alcoholic fatty liver is divided into two types: primary and secondary. The primary type is related to insulin resistance and genetics, and the secondary type is related to obesity, diabetes, hyperlipidemia, and the environment. [0003] At present, the existing drugs for the treatment of NAFLD mainly include: ①Insulin enhancers: rosiglitazone and pioglitazone, which are thiazolidinediones, can r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/047A61P1/16
Inventor 冯海华张迪韦云飞金美玉严斯如覃海燕王齐王建锋邱家章
Owner JILIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com